{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:12:08Z","timestamp":1760609528976,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","plefa.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.plefa.2023.102574","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T20:13:57Z","timestamp":1680898437000},"page":"102574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["An open-label, multicenter, phase 2 study of a food enriched with docosahexaenoic acid in adults with sickle cell disease"],"prefix":"10.1016","volume":"193","author":[{"given":"K.V.","family":"Giriraja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.K.","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sancilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.plefa.2023.102574_bib0001","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"issue":"16","key":"10.1016\/j.plefa.2023.102574_bib0002","first-page":"1120","article-title":"Pain in sickle cell disease","volume":"323","author":"R","year":"1990","journal-title":"N. English J. Med."},{"issue":"9757","key":"10.1016\/j.plefa.2023.102574_bib0003","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.plefa.2023.102574_bib0004","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/asheducation-2017.1.435","article-title":"Chronic organ failure in adult sickle cell disease","volume":"2017","author":"Vichinsky","year":"2017","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.plefa.2023.102574_bib0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.trsl.2015.07.001","article-title":"Inflammatory targets of therapy in sickle cell disease","volume":"167","author":"Owusu-Ansah","year":"2016","journal-title":"Transl. Res."},{"issue":"8","key":"10.1016\/j.plefa.2023.102574_bib0006","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s002770000173","article-title":"The role of cytokines in sickle cell disease","volume":"79","author":"Makis","year":"2000","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.plefa.2023.102574_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10245332.2018.1498441","article-title":"Oxidative stress, antioxidant capacity, biomolecule damage, and inflammation symptoms of sickle cell disease in children","volume":"24","author":"Biswal","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.plefa.2023.102574_bib0009","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/archinte.166.3.366","article-title":"C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease","volume":"166","author":"L","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.plefa.2023.102574_bib0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2141.2009.08013.x","article-title":"Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises","volume":"148","author":"Krishnan","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.plefa.2023.102574_bib0011","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCRESAHA.116.304577","article-title":"Iron, inflammation, and early death in adults with sickle cell disease","volume":"116","author":"Van Beers","year":"2015","journal-title":"Circ. Res."},{"issue":"20","key":"10.1016\/j.plefa.2023.102574_bib0012","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1182\/bloodadvances.2019000193","article-title":"Role of the coagulation system in the pathogenesis of sickle cell disease","volume":"3","author":"Nasimuzzaman","year":"2019","journal-title":"Blood Adv."},{"issue":"15","key":"10.1016\/j.plefa.2023.102574_bib0013","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2018021444","article-title":"Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)","volume":"2","author":"Daak","year":"2018","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.plefa.2023.102574_bib0014","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41573-018-0003-2","article-title":"Therapeutic strategies for sickle cell disease: towards a multi-agent approach","volume":"18","author":"Telen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.plefa.2023.102574_bib0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/nu2030355","article-title":"Omega-3 fatty acids and inflammatory processes","volume":"2","author":"Calder","year":"2010","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.plefa.2023.102574_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu8030128","article-title":"An increase in the Omega-6\/Omega-3 fatty acid ratio increases the risk for obesity","volume":"8","author":"Simopoulos","year":"2016","journal-title":"Nutrients"},{"issue":"February","key":"10.1016\/j.plefa.2023.102574_bib0017","article-title":"Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell disease","volume":"52","author":"Daak","year":"2020","journal-title":"Complement. Ther. Med."},{"key":"10.1016\/j.plefa.2023.102574_bib0018","series-title":"Proc. Nutr. Soc.","first-page":"215","article-title":"The differential effects of EPA and DHA on cardiovascular risk factors","volume":"70","author":"Cottin","year":"2011"},{"key":"10.1016\/j.plefa.2023.102574_bib0019","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1177\/0148607115595980","article-title":"Functional roles of fatty acids and their effects on human health","volume":"39","author":"Calder","year":"2015","journal-title":"J. Parenter. Enter. Nutr."},{"issue":"6","key":"10.1016\/j.plefa.2023.102574_bib0020","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3181\/0711-MR-311","article-title":"The importance of the omega-6\/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases","volume":"233","author":"Simopoulos","year":"2008","journal-title":"Exp. Biol. Med."},{"issue":"9","key":"10.1016\/j.plefa.2023.102574_bib0021","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/clc.23220","article-title":"Rounding the corner on residual risk: implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease","volume":"42","author":"Baum","year":"2019","journal-title":"Clin. Cardiol."},{"issue":"2","key":"10.1016\/j.plefa.2023.102574_bib0022","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cardiores.2006.08.019","article-title":"Cardiovascular benefits of omega-3 fatty acids","volume":"73","author":"von Schacky","year":"2007","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.plefa.2023.102574_bib0023","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10238-014-0293-6","article-title":"LC\u2013MS\/MS analysis of plasma polyunsaturated fatty acids in patients with homozygous sickle cell disease","volume":"15","author":"Aslan","year":"2015","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.plefa.2023.102574_bib0024","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bcmd.2015.03.014","article-title":"Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-\u03baB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease","volume":"55","author":"Daak","year":"2015","journal-title":"Blood Cells, Mol. Dis."},{"key":"10.1016\/j.plefa.2023.102574_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/718014","article-title":"Hydroxyurea therapy mobilises arachidonic acid from inner cell membrane aminophospholipids in patients with homozygous sickle cell disease","volume":"2011","author":"Daak","year":"2011","journal-title":"J. Lipids"},{"key":"10.1016\/j.plefa.2023.102574_bib0027","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.plipres.2016.05.001","article-title":"Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults","volume":"63","author":"Stark","year":"2016","journal-title":"Prog. Lipid Res."},{"issue":"6","key":"10.1016\/j.plefa.2023.102574_bib0028","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/ajcn\/86.5.1621","article-title":"Comparison of the effects of fish and fish-oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids","volume":"86","author":"Harris","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"issue":"6","key":"10.1016\/j.plefa.2023.102574_bib0029","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jada.2009.03.006","article-title":"Enhanced Absorption of n-3 Fatty Acids from Emulsified Compared with Encapsulated Fish Oil","volume":"109","author":"Raatz","year":"2009","journal-title":"J. Am. Diet. Assoc."},{"issue":"4","key":"10.1016\/j.plefa.2023.102574_bib0030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.plipres.2013.04.004","article-title":"Multiscale structures of lipids in foods as parameters affecting fatty acid bioavailability and lipid metabolism","volume":"52","author":"Michalski","year":"2013","journal-title":"Prog. Lipid Res."},{"issue":"5","key":"10.1016\/j.plefa.2023.102574_bib0031","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11745-015-4100-2","article-title":"Enhanced bioavailability of EPA from emulsified fish oil preparations versus capsular triacylglycerol","volume":"51","author":"Raatz","year":"2016","journal-title":"Lipids"},{"key":"10.1016\/j.plefa.2023.102574_bib0032","doi-asserted-by":"crossref","unstructured":"T.L. Savitt and M.F. Goldberg, \u201cHerrick's 1910 case report of sickle cell anemia-the rest of the story,\u201d vol. 261, no. 2, pp. 266\u2013271, 1989.","DOI":"10.1001\/jama.1989.03420020120042"},{"issue":"19","key":"10.1016\/j.plefa.2023.102574_bib0034","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/CIRCULATIONAHA.113.002731","article-title":"Omega-3 fatty acid blood levels: clinical significance and controversy","volume":"128","author":"Superko","year":"2013","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.plefa.2023.102574_bib0035","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-0463.2011.02751.x","article-title":"Pilot study of omega-3 fatty acid supplements in sickle cell disease","volume":"119","author":"Okpala","year":"2011","journal-title":"Apmis"},{"issue":"6","key":"10.1016\/j.plefa.2023.102574_bib0036","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1055\/s-0037-1615948","article-title":"Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids","volume":"85","author":"Tomer","year":"2001","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.plefa.2023.102574_bib0037","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0031-3955(16)36735-9","article-title":"The management of pain in sickle cell disease","volume":"36","author":"Shapiro","year":"1989","journal-title":"Pediatr. Clin. North Am."},{"issue":"1","key":"10.1016\/j.plefa.2023.102574_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-019-1174-5","article-title":"Altered HDL particle in sickle cell disease: decreased cholesterol content is associated with hemolysis, whereas decreased apolipoprotein A1 is linked to inflammation","volume":"18","author":"Yalcinkaya","year":"2019","journal-title":"Lipids Health Dis."},{"issue":"22","key":"10.1016\/j.plefa.2023.102574_bib0039","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1182\/blood.V128.22.2488.2488","article-title":"Long-term dosing in sickle cell disease subjects with GBT440, a novel HbS polymerization inhibitor","volume":"128","author":"Lehrer-Graiwer","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.plefa.2023.102574_bib0040","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.plefa.2023.102574_bib0041","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-3156.2000.00507.x","article-title":"An open comparative study of dispersible piroxicam versus soluble acetylsalicylic acid for the treatment of osteoarticular painful attack during sickle cell crisis","volume":"5","author":"Eke","year":"2000","journal-title":"Trop. Med. Int. Heal."},{"issue":"5","key":"10.1016\/j.plefa.2023.102574_bib0042","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.plefa.2023.102574_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12041017","article-title":"Blood EPA and DHA Levels in Response to Supplementation","volume":"12","author":"Sparkes","year":"2020","journal-title":"Nutrients"}],"container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327823000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327823000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:12:35Z","timestamp":1760602355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952327823000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":40,"alternative-id":["S0952327823000431"],"URL":"https:\/\/doi.org\/10.1016\/j.plefa.2023.102574","relation":{},"ISSN":["0952-3278"],"issn-type":[{"type":"print","value":"0952-3278"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label, multicenter, phase 2 study of a food enriched with docosahexaenoic acid in adults with sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins, Leukotrienes and Essential Fatty Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plefa.2023.102574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102574"}}